

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



09/857,636

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |  |   |
|--|--|--|---|
| (51) International Patent Classification <sup>7</sup> :<br>C07K 14/605, A61K 38/26   |  | A3   | (11) International Publication Number:<br>WO 00/34331           |
|  |  |  | (43) International Publication Date:<br>15 June 2000 (15.06.00) |
| (21) International Application Number:<br>PCT/EP99/09660   |  | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). |   |
| (22) International Filing Date:<br>7 December 1999 (07.12.99)  |  |  |   |
| (30) Priority Data:<br>09/206,601 7 December 1998 (07.12.98) US<br>60/111,255 7 December 1998 (07.12.98) US  |  |  |   |
| (71) Applicant (for all designated States except US): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. [FR/FR]; 51-53, rue du Docteur Blanche, F-75016 Paris (FR).   |  | Published<br>With international search report.   |   |
| (72) Inventor; and<br>(75) Inventor/Applicant (for US only): DONG, Zheng, Xin [CN/US]; 40 Angelica Drive, Framingham, MA 01701 (US).   |  | (88) Date of publication of the international search report:<br>16 November 2000 (16.11.00)  |   |
| (74) Agent: LUNT, Mark, George, Francis; Dibb Lupton Alsop, Fountain Precinct, Balm Green, Sheffield S1 1RZ (GB).  |  |  |   |
| (54) Title: ANALOGUES OF GLP-1   |  |  |   |
| (57) Abstract<br><br>The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues. |  |  |   |